Humanwell Healthcare's (SHA:600079) unit, Hubei Biomedical Industry Technology Research Institute, obtained approval from China's National Medical Products Administration for the clinical trial of HW243040 tablets, according to a Shanghai bourse filing on Wednesday.
The drug is intended for the treatment of peripheral neuropathic pain.
The pharmaceutical company's shares rose 2% during the midday trade.
Jinhui (HKG:0137) has entered into sale-and-leaseback arrangements for two bulk carriers under construction, according to a Tuesday Hong Kong bourse filing.The company will sell each vessel to a unit of ICBC Financial Leasing for up to $18 million and lease them back under separate five-year bareboat charter agreements.The vessels, each with a deadweight of about 64,500 metric tonnes, are expected to be delivered in February and March 2028.
BOE Technology (SHE:000725) said its controlling shareholder, Beijing Electronics, plans to purchase company shares worth 500 million yuan to 1 billion yuan over the next six months, according to a Wednesday filing with the Shenzhen bourse.
CapitaLand India Trust (SGX:CY6U) has used SG$45.6 million, representing 30.4% of the gross proceeds of the private placement conducted earlier this year, according to a Wednesday filing to the Singapore stock exchange.Of the SG$100 million earmarked to part fund the ongoing development and construction as part of its acquisition of Building 1 of Ebisu in Bangalore, India, the manager used SG$37.3 million.The company also used SG$5.7 million of the SG$47.4 million allotted to part fund the ongoing development and construction of and acquisition of an office project in Bangalore from Maia Estates Offices.It also used SG$2.6 million to pay all the fees and expenses tied to the private placement.The company's shares were up nearly 2% in recent trade.